Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 7/20 | 0.53 |
| ▸ | HTR2C | P28335 | 7/20 | 0.53 |
| ▸ | HTR2B | P41595 | 4/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | NMT1 | P30419 | 1/20 | 0.43 |
| ▸ | MLNR | O43193 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1243975 | 0.99 | PNMT (0.52) | PNMTHTR2CHTR2BADRA2AADRA2B | |
| SCHEMBL1241257 | 0.81 | HTR2C (0.61) | PNMTHTR2CHTR2BADRA2AADRA2B | |
| SCHEMBL1077845 | 0.78 | HTR2C (0.82) | PNMTHTR2CHTR2BADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL11738740 | 0.77 | HTR2C (0.80) | PNMTHTR2CHTR2BADRA2AADRA2B | |
| SCHEMBL25212417 | 0.73 | PNMT (0.54) | PNMTHTR2CHTR2BADRA2AADRA2B | |
| SCHEMBL31528391 | 0.73 | PNMT (0.54) | PNMTHTR2CHTR2BADRA2AADRA2B | |
| SCHEMBL25266925 | 0.73 | PNMT (0.54) | PNMTHTR2CHTR2BADRA2AADRA2B | |
| SCHEMBL11483387 | 0.71 | PNMT (0.71) | PNMTHTR2CHTR2BADRA2AADRA2B | |
| SCHEMBL17056235 | 0.71 | PNMT (1.00) | PNMTHTR2CHTR2BADRA2AADRA2B | |
| SCHEMBL25252542 | 0.71 | PNMT (0.57) | PNMTHTR2CHTR2BADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1753725-B1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | SANOFI SA (FR) | 2013-02-27 | — | — | EP | claimed |
| US-8273733-B2 | Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics | SANOFI (FR) | 2012-09-25 | — | — | US | claimed |
| US-20110028475-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2011-02-03 | — | — | US | claimed |
| US-7833999-B2 | Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics | SANOFI-AVENTIS (FR) | 2010-11-16 | — | — | US | claimed |
| US-20070105834-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2007-05-10 | — | — | US | claimed |
| EP-1753725-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2007-02-21 | — | — | EP | claimed |
| WO-2005118547-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2005-12-15 | — | — | WO | claimed |
| US-8524700-B2 | Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics | SANOFI (FR) | 2013-09-03 | — | — | US | disclosed |
| US-8524700-B2 | Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics | SANOFI (FR) | 2013-09-03 | — | — | US | disclosed |
| US-8524700-B2 | Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics | SANOFI (FR) | 2013-09-03 | — | — | US | disclosed |
| EP-1753725-B1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | SANOFI SA (FR) | 2013-02-27 | — | — | EP | disclosed |
| EP-1753725-B1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | SANOFI SA (FR) | 2013-02-27 | — | — | EP | disclosed |
| US-20120323003-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | SANOFI (FR) | 2012-12-20 | — | — | US | disclosed |
| US-7833999-B2 | Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics | SANOFI-AVENTIS (FR) | 2010-11-16 | — | — | US | disclosed |
| US-7833999-B2 | Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics | SANOFI-AVENTIS (FR) | 2010-11-16 | — | — | US | disclosed |
| US-20070105834-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2007-05-10 | — | — | US | disclosed |
| US-20070105834-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2007-05-10 | — | — | US | disclosed |
| US-20070105834-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2007-05-10 | — | — | US | disclosed |
| EP-1753725-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005118547-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120323003-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | BACE1, HTR2B, KCNQ2 | PNMT 59/4885HTR2C 26/4885HTR2B 2/4885 |
| US-20070105834-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | BACE1, SLC6A2, KCNQ2 | PNMT 30/4885HTR2C 23/4885HTR2B 25/4885 |
| US-20110028475-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | BACE1, HTR2B, KCNQ2 | PNMT 59/4885HTR2C 26/4885HTR2B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.